Heart failure is a leading cause of morbidity and mortality, and ERBB4 signaling has been proposed as a potential therapeutic target. Here they identify small molecule ERBB4 agonists capable of decreasing cardiomyocyte damage and fibrosis in models of cardiovascular disease.
- Julie M. T. Cools
- Bo K. Goovaerts
- Vincent F. M. Segers
